Ipsen hopeful for corabotase as Botox alternative after positive Phase II

Ipsen (Euronext: IPN; ADR: IPSEY) reported Phase II data for corabotase in moderate-to-severe glabellar lines. The trial showed that 60.8% of patients treated with corabotase maintained a clinically meaningful reduction in line severity at Week 24, compared with 36.7% for Ipsen's own Dysport (abobotulinumtoxinA) and 0.2% for placebo — an early durability signal that if confirmed in Phase III could differentiate the molecule within a crowded botulinum toxin market.

The LANTIC trial is a Phase I/II study enrolling 727 patients to evaluate the safety and efficacy of corabotase across three upper facial indications: glabellar lines, forehead lines, and lateral canthal lines. The data presented at the 2026 Scale Symposium in Nashville drew from Stage 1, Step 3 of the trial — a dose-finding, comparator-controlled cohort of 183 patients with moderate-to-severe glabellar lines evaluated against placebo and abobotulinumtoxinA.

Key results from the Phase II corabotase data

At Week 4, 66% of patients receiving corabotase at the 50ng dose achieved the primary endpoint — a composite ≥2-grade improvement in glabellar line severity — versus 0% for placebo (p=0.0001). AbobotulinumtoxinA produced a 54.3% response rate at the same timepoint, though the trial was not powered for a formal head-to-head statistical comparison at Week 4.

The more notable finding came at Week 24. Sustained duration of effect, defined as an investigator-assessed score of "none" or "mild," was recorded in 60.8% of corabotase-treated patients versus 36.7% for abobotulinumtoxinA and 0.2% for placebo. At Week 36, corabotase continued to show a greater response in line severity versus abobotulinumtoxinA, though Ipsen did not disclose specific numerical values for that timepoint.

Safety findings from Stage 1 were unremarkable. Adverse event frequency was comparable across the corabotase, abobotulinumtoxinA, and placebo arms, and Ipsen reported no significant safety concerns at any evaluated dose.

Based on these data, Ipsen selected the 50ng dose for advancement into the Phase III LAURITE program. Ipsen noted that corabotase doses are expressed in nanograms and are not directly comparable with the unit-based dosing used for naturally occurring botulinum toxin products.

Mechanism: what makes corabotase a first-in-class RNI

Corabotase is not a conventional botulinum toxin. Ipsen describes it as a recombinant neuroinhibitor — a purposefully engineered biologic built from the catalytic (A) and binding (B) functional domains of botulinum neurotoxin type A, but optimized through protein engineering to increase receptor affinity, enhance cellular uptake, and improve resistance to degradation. The company designates this structural class as RNI, for recombinant neuroinhibitor, positioning corabotase as distinct from naturally derived botulinum toxin products.

Like existing botulinum toxin products, corabotase inhibits acetylcholine release at neuromuscular junctionscomplex proteins — specifically SNAP-25 — to prevent acetylcholine release and produce temporary chemical denervation of the targeted muscle. The proposed differentiator lies not in the downstream target but in the engineered molecular architecture, which Ipsen contends translates into longer-lasting inhibition of neurotransmitter release and a more sustained reduction in muscle activity than naturally derived toxins can achieve.

Corabotase's potential commercial case rests primarily on duration. The standard clinical expectation for botulinum toxin type A in glabellar lines is approximately three to four months of effect. If the Week 24 and Week 36 durability signals from LANTIC hold in a randomized Phase III setting, corabotase could offer a materially longer interval between treatments — a meaningful differentiator for patients and, potentially, for prescriber preference.

Cross-trial comparisons are limited by differences in patient populations, dosing conventions, and endpoint definitions, and the LANTIC Stage 1 data should not be read as a direct head-to-head benchmark against the broader onabotulinumtoxinA or abobotulinumtoxinA clinical databases. The 50ng corabotase dose is expressed in a unit system that Ipsen explicitly states is not comparable to toxin unit dosing, which further complicates cross-product interpretation.

Ipsen also faces the unusual competitive dynamic of running corabotase against its own marketed product. AbobotulinumtoxinA performed in LANTIC "consistently with its clinical profile," per the company — a framing that positions the comparator arm as a calibration tool rather than a target to displace, though the commercial implications of cannibalizing Dysport revenues with a successor asset will eventually require a more direct answer.

Ipsen said it expects proof-of-concept data from LANTIC for forehead lines and lateral canthal lines later in 2026, with corabotase's Phase III LAURITE program representing the next major development milestone for the glabellar lines indication.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article